Request Demo

Last update 23 Jan 2025

Atypical Squamous Cells of the Cervix

Last update 23 Jan 2025

Basic Info

Synonyms

ASC Atypical Squamous Cells, ASC H Atypical Squamous Cells, Cannot Rule Out High Grade Squamous Intra epithelial Lesion, ASC-H Atypical Squamous Cells, Cannot Rule Out High-Grade Squamous Intra-epithelial Lesion

+ [25]

Introduction

Morphological abnormalities of the cervical EPITHELIUM, usually revealed in PAP SMEAR, which do not meet the criteria for squamous CERVICAL INTRAEPITHELIAL NEOPLASIA or SQUAMOUS CELL CARCINOMAS of the CERVIX . It may be a sign of infection with certain types of human papillomavirus (HPV).or sign of a benign (not cancer) growth, such as a cyst or polyp or, in menopausal women, of low hormone levels. More testing, such as HPV test, may be needed.

Drugs associated with Atypical Squamous Cells of the Cervix

FluBHPVE6E7

Target

HPV E6 x HPV E7

Mechanism

E7 inhibitors [+1]

Active Org.

BlueSky Immunotherapies GmbH

Originator Org.-

Active Indication

HPV positive oropharyngeal squamous cell carcinoma [+5]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

pNGVL4aCRTE6E7L2

Target-

Mechanism

Immunostimulants

Active Org.

The Johns Hopkins University [+2]

Originator Org.

The University of Alabama at Birmingham

Active Indication

Atypical Squamous Cells of the Cervix [+2]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

GTL-001

Target-

Mechanism

CD4-positive T-lymphocytes stimulants [+1]

Active Org.-

Originator Org.

Genticel SA

Active Indication-

Inactive Indication

Atypical Squamous Cells of the Cervix [+4]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Atypical Squamous Cells of the Cervix

NCT05829629

/ RecruitingPhase 1

Randomised, Double-blind, Placebo-controlled Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women With NILM, ASC-US, LSIL or Low-grade CIN

BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1).

Start Date12 Sep 2023

Sponsor / Collaborator

BlueSky Immunotherapies GmbH

NCT03913117

/ RecruitingPhase 1IIT

Phase I Clinical Trial Assessing the Safety and Feasibility of Intramuscular pNGVL4aCRTE6E7L2 and TA-CIN Administration for the Treatment of Patients With Persistent HPV16+ ASC-US or LSIL

Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine

Start Date10 Jul 2023

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

NCT05613283

/ Active, not recruitingNot ApplicableIIT

Primary Cervical Cancer Screening by Self-sampling HPV Test

Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider, which is labor consuming and the coverage and compliance are both relatively low in some areas. Non-invasive hrHPV self-sampling test appears to be more acceptable and may improve the HPV screening coverage. This study aims to evaluate the clinical performance of a newly developed urine/vaginal self-sampling hrHPV test in Cervical cancer screening.

Start Date19 Nov 2022

Sponsor / Collaborator

Peking University People's Hospital

100 Clinical Results associated with Atypical Squamous Cells of the Cervix

100 Translational Medicine associated with Atypical Squamous Cells of the Cervix

0 Patents (Medical) associated with Atypical Squamous Cells of the Cervix

1,266

Literatures (Medical) associated with Atypical Squamous Cells of the Cervix

01 Mar 2025·Diagnostic Microbiology and Infectious Disease

Comparative efficacy of HPV 16/18 DNA and E6/E7 mRNA testing in detecting high-grade cervical lesions (CIN2+) in women with cervical biopsies

Article

Author: Sadeghi, Hamid ; Naserpour-Farivar, Taghi ; Aslanimehr, Masoumeh ; Samiee-Rad, Fatemeh ; Benvari, Sepideh

The study evaluated the efficacy of HPV 16/18 E6/E7 mRNA detection in women with abnormal cervical histology. A total of 99 cervical biopsy samples were analyzed, including 49 benign, 16 with cervical intraepithelial neoplasia grade 1 (CIN1), 9 with CIN2/3, and 25 with cervical cancers. Samples were tested for HPV 16/18 using both DNA and mRNA RT-PCR methods. The findings revealed a sensitivity of 85.3 % (29/34) for the HPV DNA test and 76.5 % (26/34) for the mRNA test in detecting CIN2+ lesions. Notably, the E6/E7 mRNA test demonstrated greater specificity for CIN2+ at 75.4 % (49/65), compared to 52.3 % (34/65) for the DNA test. The prevalence of positive results for both tests increased with the severity of squamous cell abnormalities. However, the HPV 16/18 E6/E7 mRNA test provided superior specificity, making it a more effective method for cervical cancer screening in this region, offering more precise results than DNA testing alone.

01 Feb 2025·International Journal of Gynecology & Obstetrics

Review of triage strategies for atypical squamous cells of undetermined significance among young women

Review

Author: Cubaka Ntamushigo, Jeremie ; Motshedisi Sebitloane, Hannah

AbstractIn the present study we reviewed the existing literature regarding management approaches for ASC‐US and highlight their pros and cons. The ASC‐US entity emerged from Bethesda classification 2001. We conducted this review using search words ASC‐US triage, ASC‐US management in young women, triage tests for ASC‐US, and ASC‐US outcome from the English literature. We included different cervical cancer policies (American, European and for WHO) and research articles published on ASC‐US in young women from the year 2001. We searched in Google Scholar, PubMed, MEDLINE (NCBI) library, Embase (Elsevier), Wiley online library as well as Cochrane library. We defined young women as aged 30 years and below. We identified 52 articles which focused on management approaches of ASC‐US, seven articles focused on young women aged <30 years. Five of these articles combined ASC‐US with low‐grade squamous intraepithelial lesions (ASC‐US/LSIL) while only two addressed ASC‐US as a standalone entity. The limited number of articles restricts the evidence base supporting the adoption of triage strategies. There is yet, no consensus in the literature regarding the management of ASC‐US, more so in young women below the age of 30 years. Researchers, however, agree on a few aspects, which include the necessity for applying a conservative strategy for managing ASC‐US in young women, avoiding direct referral for colposcopy at the initial detection of ASC‐US, and avoiding the use of human papillomavirus (HPV) testing on young women (unless living with HIV). Newer techniques such as HPV E6/E7 messenger RNA (mRNA), and dual staining p16/ki‐67, may serve as better triage to identify cases of HPV persistence and integration which may subsequently lead to preinvasive or invasive lesions.

01 Dec 2024·European Journal of Radiology

Does ultrasound guidance decrease femoral access site complications in neurointerventional procedures? A retrospective cohort study

Article

Author: Miyake, Shigeta ; Falzon, Andrew ; Phei Kee, Tze ; Maganti, Manjula ; Chung, Emily M ; Ghazimoghadam, Saba ; Krings, Timo

BACKGROUNDUltrasound has been increasingly used to guide femoral arterial access for neuroendovascular procedures. Its effect on the safety outcomes has yet to be established.PURPOSEThe purpose is to determine the effect of ultrasound-guided punctures on femoral access site complications (ASC), and to identify other potential predictors of ASC.MATERIALS AND METHODSWe conducted a retrospective analysis of all the neurovascular cases performed with femoral arterial access between Jan 2016 and Dec 2022. Two groups of patients were selected: the first group had femoral arterial puncture without ultrasound guidance between Jan 2016 and Dec 2017 while the second group received femoral arterial puncture with ultrasound guidance between July 2019 and Dec 2022. Univariable and multivariable logistic regression analysis was conducted.RESULTSA total of 2347 patients and 3181 procedures were included - 1376 in the non-ultrasound group and 1805 in the ultrasound group. The complication rate of femoral arterial access was 2 % (58/3181). There was no statistically significant difference in complication rate between the ultrasound and the non-ultrasound groups (p-value 0.821). Interventional procedures (in particular EVT), larger sheath size use (>/=7Fr) and DAPT were shown to be the independent predictors of femoral arterial ASC (p-value < 0.001), in both univariable and multivariable analyses. The use of larger sheath size and EVT procedures have lower odds of having complications in the ultrasound group compared to the non-ultrasound group (OR: 0.42 (0.09-1.83); p = 0.249 and OR: 0.64 (0.09-4.59); p = 0.663, respectively).CONCLUSIONOur study found that the use of ultrasound does not have statistically significant impact on the safety outcome of femoral arterial access in neuro-endovascular procedures. It is, however, of benefit in high-risk cases. Independent predictors of femoral ASC include interventional vs diagnostic procedures, larger sheath size and DAPT intake. In these high-risk cases, ultrasound guidance helps to minimize femoral ASC.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Atypical Squamous Cells of the Cervix

Basic Info

Related

Analysis